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Summary. Evaluation of estrogen receptor (ER) content 
is an important factor in the choice of therapy and 
prognosis of breast cancer patients. In this study, we 
demonstrate a new spectral image analysis technique for 
objective and quantitative evaluations of stained 
specimens. The SpectraCubeTM system was used to 
analyze nuclear antigens in thirteen cases of breast 
cancer stained by the immunoperoxidase method with 
hematoxylin counterstain. Spectral imaging segregated 
the spectrum of diaminobenzidine (DAB) from the 
background color of hematoxylin and a spectral index 
was calculated. The spectral index essentially agreed 
with the pathologist's index (on a scale of 0 to 3) in 
seven out of the thirteen cases. A substantial number of 
ER positive pixels was detected in the two cases scored 
as 0 by the pathologist's index. In a test case scored as 1 
by the pathologist's index we detected a significant 
number of pixels, representing 47% of the nuclei, with 
DAB-intensity values higher than the cut-off value of 
1.2. These data suggest that spectral image analysis is a 
sensitive method providing intensive information with 
high reproducibility. Our spectral imaging method is 
highly flexible, enabling the user to define the spatial 
resolution of the analyzed specimen by choosing the 
number of pixels per one nucleus. 
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Introduction 
Evaluation of hormone receptor expression in tumor 
cell nuclei is an integral part of routine breast cancer 
diagnosis (Lehr et al., 1998). Diagnosis is determined as 
a function of a number of factors such as TNM (tumor 
node metastasis) stage; tumor type and differentiation; 
patient age; hormonal, cytotoxic and immune therapeutic 
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modalities, and the duration of tamoxifen treatment. In 
addition, the estrogen (ER) and progesterone (PR) 
receptor status of the carcinoma provides important 
information for prognosis and choice of therapeutic 
approach (Bejar et al., 1998). Patients classified as ER- 
positive/PR-positive are treated with tamoxifen, which 
has proven to produce a favorable response and survival 
advantage (Tonetti and Jordan, 1997). Additionally, 
tamoxifen is  the only drug known to reduce the 
incidence of collateral disease and produces relatively 
few harmful side effects (Tonetti and Jordan, 1997). 
However, in routine breast cancer diagnosis, receptor 
expression is often quantified in arbitrary scores with 
high inter- and intraobserver variability. Therefore, a 
question is raised as to whether pathologists' subjective 
impressions of negative versus positive ER states - and 
their readings of grades of positivity - are reliable in 
determining appropriate oncological management. 
Immunohistochemical assays are most commonly 
used today to stain ER. These methods are quick, 
inexpensive and allow hormone receptor determination 
even if only small amounts of tumor tissue are available. 
Nevertheless there is no consensus regarding the method 
for scoring the results. Although the immunohisto- 
chemical technique is  easy to  standardize, its 
interpretation relies solely on subjective visual estimates, 
yielding only qualitative or at best semiquantitative 
results (Baddoura et al., 1991; Lehr et al., 1998). Most 
pathologists distinguish between positive and negative 
results based on the percentage of positive tumor cells, 
the cutoff being arbitrarily defined between 5 and 45% 
(Battifora et al., 1990; Raymond and Leong, 1990; 
Molino et al., 1995; Veronese et al., 1995; Pertschuk et 
al., 1996). The most commonly used method for 
semiquantification of the hormone-receptor status is the 
so-called H-score. The H-scores take into consideration 
both the color intensity of the immunoreactive neoplastic 
cell nuclei and the percentage of positive cells in 
histological sections of paraffin-embedded tissue stained 
with anti-hormone-receptor antibody by one of the 
commercially available immunohistochemical kits. Still, 
most of these scoring systems are cumbersome to 
Spectral imaging: estrogen receptor 
perform and are subject to high interobserver variability. 
Several attempts were made in order to employ 
image analysis techniques in the process of receptor 
quantitation. Bejar et al. (1998) measured the optical 
density of the nuclei in the digitized image file of the 
field and presented it in arbitrary gray-level units. The 
units were then divided into three equal intervals and the 
percentage of cell  nuclei in each interval was 
determined. Lehr et al. (1998) used image analysis 
software to determine the region of interest of each 
nucleus in the image and the mean value of grayscale 
units. However, both procedures ignore the contribution 
of the natural color of the specimen to the stain intensity 
of the nuclei. Furthermore, most receptor staining 
procedures apply an additional stain for the counter 
staining of the examined specimen, in order to 
differentiate between tissue and subcellular domains. 
The contribution of the background stain is thus 
extremely significant and may lead to inaccurate, and 
perhaps false, results. 
The development of spectral imaging for biological 
and medical applications introduced both fields to large 
amounts of information extracted from a single image 
(Rothmann et al., 1998a). Spectral imaging, as the 
terminology suggests, combines spectroscopy and 
imaging. In dramatic  contrast to conventional 
microscopy in which fluorochrome discrimination is 
based on the measurement of a single intensity through a 
specific optical filter, spectral imaging allows one to 
measure and analyze the full spectrum of light at all 
pixels of an image. Spectral imaging has opened up new 
possibilities for the analysis of tumors (Malik et al., 
1998), tissue-sections (Rothmann et al., 1998b), cells 
(Rothmann et al., 1997) and chromosomes (Schrock et 
al., 1996; Veldman et al., 1997). The SpectraCubeTM 
system combines spectral imaging with microscopy and 
is based on Fourier transform multi-pixel spectral 
imaging. The light intensity at any wavelength is 
measured from multiple points of an image and stored in 
a spectra cube file whose appellate signifies the two 
spatial dimensions of a flat sample (X and y) and the 
third dimension, the spectrum, representing the light 
intensity for every wavelength. The digitized data of the 
cube can be subjected to further analysis by 
mathematical methods. 
In this study we demonstrate a new generation 
technique for objective, quantitative and accurate 
evaluations of immunohistochemical hormone-receptor 
expression. Spectral imaging is applied in order to 
achieve a complete discrimination between background 
coloring and the specific staining of hormone receptors. 
Materials and methods 
lmmunohistochemical staining 
A total of 13 cases of infiltrating duct carcinoma of 
the breast were selected from a series of cases, submitted 
during the last quarter of 1998 to the department of 
Pathology, Sheba Medical Center, Tel-Hashomer, Israel. 
Formalin-fixed paraffin-embedded tissues were cut to 4 
micron thick sections and stained, under standard 
conditions by NexES (Ventana Medical Systems, 
Tucson, AZ),  using diaminobenzidine (DAB) as 
a substrate for the immunoperoxidase technique. 
Sections were counter-stained with hematoxylin. Two 
independent pathologists determined the status of ER 
and PR in 13 cases of breast carcinoma. The intensity of 
the brown reaction product in the nuclei was graded 
from 0 to 3. Unstained nuclei were graded 0 while dark 
brown nuclei were graded 3. The intensity index was 
defined as the weighted score of the combined grades of 
color intensity multiplied by the percentage of positive 
nuclei. 
Spectral image analysis 
Systematic random sampling (Gundersen and 
Jensen, 1987) was performed on the stained breast 
carcinoma specimens (Fig. 1A) followed by spectrally 
resolved imaging using the SpectraCubeTM (Applied 
Spectral Imaging, Migdal HaEmek, Israel) (Garini et al., 
1996). Measurements were made using a x40 objective 
on 10  viewing fields of 220x220 pixels. During the 
measurements all the parameters of the microscope 
remained constant. Light intensity at each wavelength in 
the range of 450-850 nm was recorded for 104 pixels 
from each field and represented as transmitted light 
spectra. The spectra were stored in a cube file. The 
spectrum of a control specimen stained only for estrogen 
receptor and the spectrum of a control specimen stained 
only by the background stain were recorded and stored 
as reference spectra (Fig. 1B). Each reference spectrum 
was assigned an arbitrary color. 
Quantification of estrogen receptors 
A quantification procedure was developed in order 
to digitize the spectral information from the specimen, 
distinguish the background from the ER signal and 
calculate the ER index (Fig. 1). We employed a spectral 
classification algorithm, which operates on the spectral 
image and calculates the degree of similarity between 
each reference spectrum and the spectrum of each pixel 
composing an image using linear combination (Fig. ID). 
In this algorithm, the pixel spectrum is expressed as a 
weighted sum of the pre-defined reference spectra. The 
weights are the spectral coefficients combined to best fit 
the pixel's spectrum. The linear combination finds how 
much of each reference spectrum must be added to best 
match the pixel's spectrum. Given spectrum S at pixel 
x,y, the linear combination algorithm will find the set of 
coefficients wk such that 
Where e is as small as possible. 
Each reference spectrum is given a different weight 
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wk in this sum, in an attempt to match the pixel's 
spectrum Sx,y as closely as possible. Each pixel x,y is 
given the color of the reference spectrum Rk with the 
largest coefficient wk. 
The classification was performed on normalized 
spectra in order to neutralize the effect of intensity 
differences between the reference and the pixel's spectra. 
The data was stored in a cube file where two dimensions 
are of the flat sample (X and y), and the third dimension 
is the spectral coefficient divided into two bands, one of 
the hormone-receptor spectrum and the other of the 
background spectrum. The spectral coefficients of the 
hormone receptor spectrum were normalized to 1. The 
multiplication (Fig. 1E) of the relative contribution of 
the hormone-receptor spectrum wR1 by the intensity of 
each pixel Ix,y (from the negative image of the original 
grayscale image, Fig. 1C) revealed the absolute net 
intensity of the ER staining for every pixel (Fig. IF). 
For each case, positive and negative controls were 
determined from a control sample with a previously 
established diagnosis, which was processed and stained 
with the specimen. Each file, representing a single field 
in the specimen, was opened and processed as follows: 
The total intensity and the number of significant pixels 
(intensity value higher than the lowest control value) 
were calculated. The sum of intensity of all the fields of 
a specimen was divided by the total number of 
significant pixels. The procedure is summarized in 
Control 
sample: 
hematoxylin 
Specimen 
stained by 
DAB only 
Specimen 
stained by 
hematoxylin 
I Spectral analysis by SpectraCube I 
The negative image 
of the original 
image in gray scale, 
displaying the light 
intensity for every 
pixel 
L 
Classification o f  the specimen 
file using the reference spctra 
(normalized, linear combination) 
and isolation o f  the DAB 
spectnun - displaying the relative 
contribution o f  the spectrum to a 
Multiplication o f  the relative 
contribution o f  the ER spectrum 
by the intensity o f  the pixel 
produces the absolute 
contribution o f  the ER spectrum 
to the light intensity o f  the pixel 
l I 
E 
Positive and negative controls 
are determined 6om the control 
sample. 
The average intensity o f  the 
specimen is determined and the 
index is calculated. 
Spectral analysis by I I Spectral analysis by Spectracube Spectracube 
I Reference spectrum A I I Reference spectrum B I 
Fig. 1. A diagram of the ER quantification procedure. A. Spectral image analysis was 
performed on thirteen cases of breast carcinoma using the SpectraCubeTM imaging 
system. B. The spectrum of a control specimen stained only for ER and the spectrum of a 
control specimen stained only by the background stain, hematoxylin, were recorded and 
stored as reference spectra. D. The spectral classification algorithm calculated the degree 
of similarity between each reference spectrum and the spectrum of each pixel composing 
an image using linear combination. E. The multiplication of the relative contribution of the 
ER spectrum by the intensity of each pixel (from the negative image of the original 
grayscale image, C) revealed the (F) absolute net intensity of the ER staining for every 
pixel. 
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a revealed a substantial number of positive ER values, while in case 3 the 
positive ER values were low. In case 6 which was scored as 1 by both the 
0 pathologist's index and the compatible spectral index, the analysis detected 
a large number of pixels (representing 47% of the nuclei) with intensity 
Case Number values higher than the conventional cut-off value of 1.2 (dark gray). 
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Figure 2. 
Results 
Spectral quantification of ER receptors of breast 
carcinoma tumors and the control tumor revealed two 
distinct groups of specimens differing by their DAB- 
intensity levels. Although all the specimens were 
prepared in the same medical center on the same date, 
five specimens were highly stained while the other eight 
were stained lightly (Fig. 3A). However, since all the 
data were digitized it was possible to correct the DAB- 
intensity according to the control values. 
Specimen 
Grayscale image 1 
Negative image 1 
DAB- 
intensity 
The spectral data obtained represented the DAB- 
intensities of the ER staining for every pixel of the field. 
The values of DAB-intensities varied from level 0 to 255 
on a continuous scale. Thus, the spectral method 
presented large amounts of data, which could be 
translated to any other scaling method. In order to 
display the spectral results in the common pathologist's 
scale (0 to 3), we used the pathologist's index for the 
control specimen to calculate the compatible spectral 
index of the specimen pig .  3B). As shown in Figure 3B, 
while the compatible spectral index essentially agreed 
with the pathologist's index of cases 1, 6, 9, 10, 11, 12 
and 13, some conflict was observed in the other cases. In 
\ 
1 Classification 
I 
1 Single spectrum 
I 
Multiplication 
Calculation of ER index 
DAB- 
spectrum 
Fig. 2. A summarizing diagram of the 
ER quantification procedure. A breast 
carcinoma specimen stained for ER is 
analyzed using the SpectraCubeTM. 
Spectral classification reveals a 
spectral-map where the color of each 
pixel represents the reference 
spectrum it best matches. The relative 
contribution of the DAB-spectrum is 
multiplied by the negative image of 
the original specimen. The output data 
is processed to generate a spectral 
index. 
Spectral imaging: estrogen receptor 
cases 2, 4, 7 and 8, the pathologist's index declared a 
much higher value than the value obtained by the 
spectral quantification. In cases 3 and 5 the spectral 
analysis detected more ER than the amount determined 
by the pathologist. 
The most intriguing and critical results were those of 
cases 3, 6, 9 and 11. The pathologist's index for these 
cases was lower than the conventional cut-off value of 
1.2 determined for tamoxifen therapy. Cases 3, 9 and 11, 
Case Number 
Case Number 
Case Number 
1 0 0 1  , , 
. . .  
. . 
. . .  
V) . . .  . . . . .  
= 80- ' ,  - : ; .  . .  
,, . . .  
. . . .  S . .  . .  ,~ ., , :.: 
, . ,.., :. . . . . . .  
.. , . .  
., , .. 
- .;. 
rC , > .  . . 
. . . . . . .  0 60- ~.,; '.,~,':~,'~' . . . . . . .  . . . . .  
initially scored as 0 by the pathologist's index, were 
analyzed using the spectral data in order to determine the 
number of pixels displaying ER values higher than the 
cut-off value. The number of pixels was then divided by 
the number of pixels of the average nucleus in the field 
to produce the percentage of cells displaying positive, 
above threshold ER values. As shown in Figure 3C, 
cases 9 and 11 contained a substantial number of 
positive ER values while in case 3 the positive ER 
values were low. The  most significant result was 
obtained for case 6 which was scored as 1 by both the 
pathologist's index and the compatible spectral index. 
However, analysis of each single pixel detected a large 
number of pixels, representing 47% of the cells, with 
intensity values higher than the cut-off value. 
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Discussion 
In this study, we aimed to develop a new spectral 
analysis technique for the evaluation of hormone 
receptors, free of all the pitfalls of the common, 
subjective evaluation method. Several studies have 
discussed the question as to what degree do pathologists 
reliably and consistently recognize negative scores and 
three grades of ER status. Bejar et al. (1998) has 
indicated that a pathologist's skill in consistently 
discriminating between negative and weakly positive 
scores is  dubious at best. The human brain can 
discriminate up to 64 gray levels, in contrast to the 256 
levels of light intensity detected by computer-assisted 
image analysis. In addition, humans have difficulties in 
quantifying exactly what they see. Recognition of shifts 
from negative (0) to weakly positive (1) grades is neither 
concise nor reproducible. The same holds true for 
distinctions between grades 1 and 2 and between grades 
2 and 3 (Bejar et al., 1998). 
The lack of consistency among the cutoff values 
chosen by laboratories to define an estrogen receptor 
negative result also complicates the interpretation of the 
data (Kinsel et al., 1989; Tesch et al., 1993; Detre et al., 
1995; Osborne, 1998). Using immunohistochemical 
analysis, some laboratories include tumors in which l 0  
or even 20 percent of the cells contain estrogen receptors 
among those designated estrogen-receptor-negative 
(Osborne, 1998). Unless those laboratories have justified 
their cutoff values with clinical follow-up data, many 
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Flg. 3. A. Spectral quantification of ER receptors in control breast 
carcinoma tumor. The specimens prepared under standard conditions 
reveal two distinct levels of DAB-intensities presented in arbitrary units 
(AU). B. The pathologist's index on a scale of 0 to 3 (light gray) and the 
compatible spectral index (dark gray) which were calculated for each case. 
As shown, the compatible spectral index agreed with the pathologist's index 
of cases 1, 6 ,  9, 10, 1 l,  12 and 13; in cases 2, 4, 7 and 8, the pathologist's 
index declared a higher value. C. Plxel-by-pixel analysis of cases 9 and 11 
revealed a substantial number of positive ER values, while in case 3 the 
positive ER values were low. In case 6 which was scored as 1 by both the 
pathologist's index and the compatible spectral index, the analysis detected 
a large number of pixels (representing 47% of the nuclei) with intensity 
values higher than the conventional cut-off value of 1.2 (dark gray). 
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patients may be misclassified as having estrogen- 
receptor-negative tumors and thus may not be offered 
tamoxifen treatment (Osborne, 1998). This may explain 
why tamoxifen was found beneficial in women with 
estrogen receptor negative tumors (Osborne, 1998). 
Other data suggest that tumors with any detectable level 
of estrogen receptors (with even 1% of cells staining 
positivey should -be considered positive (Knight et al, 
1980). 
A vast number of studies has been dedicated to 
reducing the effect of environmental conditions on the 
scoring procedure by developing an objective and 
quantitative evaluation method (Rostagno et al., 1994; 
Lehr et al., 1998). Image analysis has introduced several 
advantages to the quantitation of hormone receptor 
status and the pathological diagnosis (el-Badawy et al., 
1991; Rostagno et al., 1994; Cavaliere et al., 1996; 
Cohen, 1996; Bejar et al., 1998; Kirkegaard et al., 1998; 
Lehr et al., 1998). Data is collected and digitized from 
several fields in the specimen enabling mathematical 
manipulations and processing of the information 
obtained. Pathological practice dictates the rules and 
conditions for decision-making and final scoring. This 
process can be computerized to utilize the digitized data 
and to produce an objective, unbiased result. The result 
obtained by computerized image analysis is presented on 
a continuous scale providing the pathologist with a more 
accurate information regarding the specimen. 
Automation of all the steps leading to the diagnostic 
result could yield an easy-to-use system with rapid 
performance. 
Image analysis of the DAB-stained specimen, 
whether analyzed manually or by computerized 
methods, measures the level of nuclear staining while 
disregarding the possible contribution of the illuminating 
light source of the microscope to the diagnosis. The level 
of ER in a specific specimen could vary from one 
diagnostic determination to the other due to the use of 
different intensity levels of illumination. In addition, 
most receptor staining procedures apply an additional 
stain for the counter staining of the examined specimen. 
The contribution of the background staining is thus 
extremely significant and may lead to inaccurate, and 
perhaps false, results. 
Spectral image analysis enables the differentiation of 
distinct color constituents according to their unique 
spectra. Rostagno et al. (1994) based their analysis of 
estrogen receptors on the different light absorption 
spectra of the chromogen diaminobenzidine and Harris's 
hematoxylin coloration when exposed to light of 
differing wavelengths. The SpectraCubeTM system, used 
in the present study, offers some new advantages to 
spectral imaging by enabling the measurement and 
analysis of the full spectrum (450-850nm) of light at all 
pixels of an image. The spectral image presents a three 
dimensional array of data which combines precise 
spectral information with two-dimensional spatial 
correlation. The analysis of a spectral image creates a 
unique database, which enables the extraction of features 
and the evaluation of quantities from multi-point spectral 
information, impossible to obtain otherwise. 
In the present study, we used the SpectraCubeTM for 
the evaluation of the ER status in thirteen cases of breast 
carcinoma. The ER spectrum was distinguished from 
other colored elements in order to obtain a net 
contribution of hormone-receptor staining. Variability in 
DAB-intensities of the control samples was revealed by 
spectral analysis. These distinctions, hardly apparent to 
the human eye, can lead to a false negative result for 
lightly stained receptors and affect the clinicians' choice 
of treatment. This  situation was resolved by the 
correction of the light intensity values of the specimens 
by the previously scored control samples. The 
calculation of the spectral index included the segregation 
of the ER spectrum from other spectral elements and the 
calculation of the average DAB-intensity per specimen. 
The net spectral index of ER was based solely on the 
DAB-intensity with the exclusion of any environmental 
noise such as the intensity of the light source and the 
counter-staining. Comparison between the pathologist's 
index and the calculated spectral index was achieved by 
calculation of a compatible spectral index based on the 
same pathologist's scale (0 to 3) used previously to score 
the 13 cases. The compatible spectral index essentially 
agreed with the pathologist's index in 7 out of the 13 
cases. However, the conflict observed in the rest of the 
cases may be the result of the different approaches used 
by the two methods. While the pathologists consider a 
whole nucleus as the basic unit for scoring, the spectral 
image analysis relates to each individual pixel in a 
'positive' nucleus composed of 500050 pixels. The DAB- 
intensity in each pixel is a function of the local 
concentration of ER. In order to extract more 
information from the spectral database of each specimen, 
we applied a pixel-by-pixel analysis. We detected a 
substantial number of ER positive pixels in the 2 cases 
scored as 0 by the pathologist's index. In addition, a 
significant number of pixels (representing 47% of the 
nuclei) with DAB-intensity values higher than the 
conventional cut-off value of 1.2 was discovered in a 
case scored as 1 by the pathologist's index. These pixels, 
either distributed over the specimen or locally 
positioned, are equal to a number of highly stained 
nuclei and thus may affect the choice of treatment. In 
addition, these results indicate that a decision-support 
system based on a single factor is neither sufficient nor 
reliable. 
Our spectral quantification method is extremely 
flexible, enabling the user to determine the desired 
spectral resolution or the number of pixels per one 
nucleus and the number of analyzed fields per one 
specimen. The highly intensive information obtained is 
digitized, allowing automated calculation with high 
reproducibility. The analysis does not require any special 
preparation of the specimen beyond the routine 
immunohistochemical staining and thus is easy to 
master. Spectral imaging succeeded in segregating DAB 
and hematoxylin yielding the pure value of ER. The 
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ability of spectral imaging to segregate distinct spectra 
could contribute greatly to the analysis of multi-stained 
specimens. 
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